866-997-4948 (US-Canada Toll Free)

La Merie Publishing is an independent business information provider for the biopharmaceutical industry. We publish reports and newsletters, and provide the service of preparing tailor-made reports. The full range of our products are commercialized via our associated biotech portal PipelineReview.com and reselling partners.

Show More

La Merie Publishing is an independent business information provider for the biopharmaceutical industry. We publish reports and newsletters, and provide the service of preparing tailor-made reports. The full range of our products are commercialized via our associated biotech portal PipelineReview.com and reselling partners.

Show Less
  • Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors

    Apr 2015

    By La Merie Publishing

    Therapeutic Area

    414 Pages

    Competitor Analysis: Therapeutic Antibodies 2015: Biosimilars & Biosuperiors This Competitive Intelligence Report about Therapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of April...

    USD 1500View Report
  • Engineered TCR and CAR Immunotherapeutics 2015

    Mar 2015

    By La Merie Publishing

    Machines

    201 Pages

    The engineered T cell receptor (TCR) for targeting of intracellular targets not druggable by conventional antibody technologies, and specifically targeted engineered T cells are two of the most promising emerging technologies in immuno-oncology apart from immune checkpoint modulators. The relevance of TCR targeting and engineered T cells is reflected by impressive clinical results with...

    USD 2630View Report
  • Recombinant Coagulation Factors 2015: Maturation of recombinant clotting factor pipeline and emergence of gene therapy and alternative procoagulants

    Dec 2014

    By La Merie Publishing

    Therapeutic Area

    210 Pages

    This report provides an update of recombinant coagulation factors used for controlling bleeding of hemophilia A and B and other bleeding disorders. 2013 sales figures and 2014 nine-month sales data are analyzed to evaluate commercial development of the market under the light of a strong pipeline and entry of new competitor products into the market. The profiles of drug candidates in...

    USD 2795View Report
  • Peptide Therapeutics Pipeline Database: 1-Year Subscription

    Nov 2014

    By La Merie Publishing

    Therapeutic Area

    0 Pages

    Subscription to La Merie Publishing’s proprietary Peptide Therapeutics Pipeline Database provides online access to Peptide Therapeutics on the market and in research & development. The peptide segment database contains about 900 files. Each project (file) is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use of the R&D database of...

    USD 1016View Report
  • Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders

    Jul 2014

    By La Merie Publishing

    Therapeutic Area

    169 Pages

    This business report from July 2014 is based on the identification, description and assessment of all relevant stakeholders in the field of botulinum neurotoxins. The report analyzes the existing product portfolios in regulated and less regulated markets, commercial information, and measures to maintain sales and market shares by upside indications and life cycle management measures. The...

    USD 2656View Report
  • Competitor Analysis: Cancer Vaccines

    Mar 2014

    By La Merie Publishing

    Oncology

    179 Pages

    The present Competitive Intelligence report about Cancer Vaccines provides a competitor evaluation in the field of novel prophylactic and therapeutic vaccines to fight cancer as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail...

    USD 1112View Report
  • Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014

    Mar 2014

    By La Merie Publishing

    Therapeutic Area

    386 Pages

    Biosimilar and Biosuperior Therapeutic Antibodies 2014 The present Competitive Intelligence Report about Biosimilar and Biosuperior Therapeutic Antibodies 2014 provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of March 2014. Marketed...

    USD 1523View Report
  • Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis

    Jan 2014

    By La Merie Publishing

    Pharmaceutical

    347 Pages

    The report entitled „Antibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis“ published in January 2014 is based on the evaluation of more than 90 companies. The report analyzes established and new antibody-drug conjugate (ADC) technologies, business activities and opportunities and assesses more than 100 ADC development and research programs. The...

    USD 2873View Report
  • The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry

    Oct 2013

    By La Merie Publishing

    Biotechnology

    84 Pages

    A  comparative analysis and assessment of TCR technologies, pipelines and  companies from an industry perspective Therapeutic monoclonal antibodies have become an  increasingly successful treatment modality with sales of US$ 65 bln in the year  2012 and with an average (continuous) annual growth rate from 2006 to 2012 of  18.9%. While antibody technologies...

    USD 1919View Report
  • Protein Target & Pipeline Database: 1-Year Subscription

    Jul 2013

    By La Merie Publishing

    ICT

    0 Pages

    Product description Subscription to La Merie Publishing’s proprietary Protein Database provides online access to information about more than 1900 project entries for therapeutic proteins on the market and in research & development. Pre-established and free search functions allow to identify proteins according to their Target (e.g. Factor VIII, G-CSF, FSH)...

    USD 1588View Report
  • Competitor Analysis ErbB / Her Receptor Antagonists

    Jul 2013

    By La Merie Publishing

    Pharmaceutical

    168 Pages

    The present Competitive Intelligence Report about antagonists of the ErbB/Her receptor pathway provides a competitor evaluation in the field of ErbB1 (EGF-R), ErbB2 (Her), ErbB3 (Her) and ErbB4 (Her4) receptor targeting molecules for treatment of cancer as of July 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since...

  • Antibody Target, Technology & Pipeline Database: 1-Year Subscription

    Jul 2013

    By La Merie Publishing

    Pharmaceutical

    0 Pages

    Subscription to La Merie Publishing’s proprietary Antibody Database provides online access to information about more than 2,400 project entries for therapeutic antibodies on the market and in research & development. Pre-established and free search functions allow to identify antibodies according to their Technology (e.g. antibody-drug conjugate, bispecific,...

    USD 1705View Report
  • Recombinant Coagulation Factors 2013 - The Race to Market and for Market Shares: A Technology & Pipeline Assessment and Corporate Benchmarking Analysis

    Jun 2013

    By La Merie Publishing

    Biotechnology

    129 Pages

    A Technology & Pipeline Assessment and Corporate Benchmarking Analysis The report “Recombinant Coagulation Factors 2013 – The Race to Market and for Market Shares: Technology & Pipeline Assessment and Corporate Benchmarking Analysis” of June 2013 describes a market forecast based on growth of historical sales of recombinant coagulation factors. The report...

    USD 2767View Report
  • Competitive Information Service Package - 1-year subscription

    May 2013

    By La Merie Publishing

    Biopharmaceutical

    0 Pages

    Subscription to this product provides access during one year to three Competitive Intelligence information products released by La Merie Publishing with great cost savings: 1) Flat-Rate Access to La Merie Publishing Reports: Access during one year to all existing and new reports produced by La Merie Publishing and listed in the online store. Among La Merie Publishing...

    USD 7871View Report
  • Competitor Analysis: Coagulation Factors

    May 2013

    By La Merie Publishing

    Medical Imaging

    158 Pages

    Competitor Analysis: Coagulation Factors Product description The Competitive Intelligence Report Coagulation Factors provides a competitor analysis of plasma-derived and recombinant coagulation factors for topical or systemic administration to treat hereditary or acquired coagulation disorders as of May 2013. Purchase of the pdf report includes a 6-month online...

  • Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors

    May 2013

    By La Merie Publishing

    Biopharmaceutical

    301 Pages

    Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and...

    USD 2092View Report
  • Competitor Analysis: Antibody-Drug Conjugates (ADC)

    Apr 2013

    By La Merie Publishing

    Healthcare

    104 Pages

    Product description The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated via a linker with a drug payload for treatment of cancer as of April 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the...

  • Influence of Antibody Attributes on Clinical Success - A Technology and Coporate Benchmark Analysis

    Mar 2013

    By La Merie Publishing

    Biotechnology

    88 Pages

    The analytical report „Influence of Antibody Attributes on Clinical Success – A Technology and Coporate Benchmark Analysis“ evaluates the impact of a number of antibody attributes on the success rate of antibodies in clinical development. Among the antibody attributes studied  in this investigation are antibody generation technology, animal species of the parental...

    USD 1203View Report
  • Antibody Technologies and Attrition Rates - an industry analysis 2013

    Mar 2013

    By La Merie Publishing

    Pharmaceutical

    607 Pages

    The report “Antibody Technologies and Attrition Rates – an industry analysis 2013” is based on the identification of the antibody generation technologies of 504 naked antibodies in clinical or market stages. Information was retrieved from scientific and corporate publications as well as from patent and legal literature. The report provides descriptive statistics of the...

    USD 2781View Report
  • Competitor Analysis: Toll-Like Receptor (TLR) Agonists & Antagonists

    Dec 2012

    By La Merie Publishing

    Healthcare

    178 Pages

    Toll-Like Receptor (TLR) Agonists & Antagonists Product description The Competitive Intelligence Report Toll-Like Receptor (TLR) Agonists & Antagonists provides a competitor analysis in the development pipeline of novel small molecules, proteins, DNA, RNA and vaccines targeting the toll-like receptors (TLR) for treatment or prevention of cancer, infectious...

  • Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012

    Mar 2012

    By La Merie Publishing

    Healthcare

    231 Pages

    Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012 This report “ Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012 ” published in March 2012 provides a compilation of business, commercial, clinical and scientific information about GLP-1 receptor agonists. A comprehensive...

    USD 2524View Report
  • Competitor Analysis: Anti-Infective Antibodies

    Nov 2011

    By La Merie Publishing

    Healthcare

    160 Pages

    Competitor Analysis: Anti-Infective Antibodies Product description The present Competitive Intelligence Report about Anti-Infective Antibodies provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies and human plasma-derived immunoglobulins and hyperimmunes for post-exposure prophylaxis and treatment of infectious diseases as...

    USD 1029View Report
  • Coagulation Factors 2011. Who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis

    Oct 2011

    By La Merie Publishing

    Cardiovascular Devices

    162 Pages

    Coagulation Factors 2011 who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis Product description The report Coagulation Factors 2011 who does meet the market needs?  A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis provides a description, evaluation and assessment of the recombinant...

    USD 3087View Report
  • Vaccine Pipeline Database: 1-Year Subscription

    Oct 2011

    By La Merie Publishing

    Vaccines

    0 Pages

    Vaccine Pipeline Database: 1-Year Subscription Product description Subscription to La Merie’s proprietary Vaccine Pipeline Database provides online access to more than 1,200 project entries for prophylactic and therapeutic vaccines on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area...

    USD 1287View Report
  • Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis

    Sep 2011

    By La Merie Publishing

    ICT

    274 Pages

    Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis Product description This report “Antibody-Drug Conjugates 2011 – real breakthrough still to come: A Technology, Stakeholder and R&D Pipeline Analysis” published in September 2011 provides the most complete compilation of...

    USD 2524View Report